Evidence map›Paper›PMID 40715586›Full record

ArticleBritish journal of cancer2025

Cumulative incidence and survival outcomes of brain metastases in sarcoma: a large single center retrospective analysis.

Ayah Erjan, Kurl Jamora, Enrique Gutierrez, Anna Santiago, Adeodatus Vito Nicanor, Barbara-Ann Millar, Normand Laperriere, Tatiana Conrad, Dana Keilty, Philip Wong and 4 more

Erratum issuedAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in British journal of cancer, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

14 authors.

Ayah ErjanDepartment of Radiation Oncology, University of Toronto, Toronto, ON, Canada.ORCID http://orcid.org/0000-0002-1567-3182
Kurl JamoraDepartment of Radiation Oncology, University of Toronto, Toronto, ON, Canada.
Enrique GutierrezDepartment of Radiation Oncology, University of Toronto, Toronto, ON, Canada.
Anna SantiagoDepartment of Biostatistics, University of Toronto, Toronto, On, Canada.
Adeodatus Vito NicanorDepartment of Radiation Oncology, University of Toronto, Toronto, ON, Canada.
Barbara-Ann MillarDepartment of Radiation Oncology, University of Toronto, Toronto, ON, Canada.
Normand LaperriereDepartment of Radiation Oncology, University of Toronto, Toronto, ON, Canada.
Tatiana ConradDepartment of Radiation Oncology, University of Toronto, Toronto, ON, Canada.
Dana KeiltyDepartment of Radiation Oncology, University of Toronto, Toronto, ON, Canada.
Philip WongDepartment of Radiation Oncology, University of Toronto, Toronto, ON, Canada.
Peter ChungDepartment of Radiation Oncology, University of Toronto, Toronto, ON, Canada.
Charles CattonDepartment of Radiation Oncology, University of Toronto, Toronto, ON, Canada.
David KirschDepartment of Radiation Oncology, University of Toronto, Toronto, ON, Canada.ORCID http://orcid.org/0000-0002-2086-205X
David B ShultzDepartment of Radiation Oncology, University of Toronto, Toronto, ON, Canada. david.shultz@uhn.ca.ORCID http://orcid.org/0000-0001-8242-6555

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundThe incidence and predictors of brain metastases (BrM) from sarcoma remain poorly characterized. We aimed to determine the cumulative incidence (CuI) and risk factors for BrM.

methodsWe retrospectively analyzed data from all sarcoma patients who presented to our center (2006-2023). CuI was calculated from initial presentation to BrM, stratified by key variables. Univariable (UVA) and multivariable competing risk regression analyses (MVA) were conducted to identify risk factors.

resultsAmong 5110 sarcoma patients, 117 developed BrM. CuI rates were 1.8%, 2.4%, and 2.9% at 24, 48, and 72 months, respectively, within a median onset of 17 months. On UVA, intrathoracic primary site, alveolar soft part (ASPS), epithelioid, intimal and Rhabdomyosarcoma histologies, and stage IV at diagnosis were associated with increased CuI, while age ≥59, retroperitoneal origin and liposarcoma were associated with decreased CuI. On MVA the following remained correlated to BrM incidence: intrathoracic primary (HR 5.13), ASPS (HR 4.2), age ≥59 years (HR 0.45) and liposarcoma (HR 0.11); 44.3% presented with solitary BrM. Median survival post-BrM diagnosis was 6 months.

conclusionBrM risk in sarcoma varies by age, histology, and tumor location. Solitary metastases were common in our BrM cohort, and OS post-BrM was poor.

Indexed as

Brain NeoplasmsSarcomaAdolescentAdultAgedAged, 80 and overFemaleHumansIncidenceMaleMiddle AgedRetrospective StudiesRisk FactorsYoung Adult

Identifiers

PMID40715586
PMCPMC12603071

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.